The International Accounting Standards Board and the International Sustainability Standards Board are developing standards for rate-regulated activities and carbon.
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs to pay for the next generation of obesity medicines to come after that.
Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives on the company’s investor call faced questions about a sluggish uptake for schizophrenia drug Cobenfy as well as a highly anticipated Alzheimer’s psychosis readout for the product.
Mounjaro and Zepbound contributed more than $10 billion to the $11.98 billion in sales Lilly recorded for key products in the third quarter, despite price decreases for the GLP-1 medicines.